Major drug firms have been telling investors they'll offset patent expirations with...

|By:, SA News Editor

Major drug firms have been telling investors they'll offset patent expirations with emerging-market growth, although they may be overambitious. Cooling economies and local competition have weakened prospects for the multinationals, with E&Y calculating a $47B difference between companies' sales expectations and what they'll actually earn. Eli Lilly (LLY) and Pfizer (PFE) are among those affected.